SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-004006
Filing Date
2022-03-17
Accepted
2022-03-17 08:13:00
Documents
12
Period of Report
2022-03-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K impl-20220317.htm   iXBRL 8-K 79807
  Complete submission text file 0000950170-22-004006.txt   214776

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT impl-20220317.xsd EX-101.SCH 2485
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT impl-20220317_lab.xml EX-101.LAB 19184
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT impl-20220317_pre.xml EX-101.PRE 12073
6 EXTRACTED XBRL INSTANCE DOCUMENT impl-20220317_htm.xml XML 5108
Mailing Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119 206-568-1466
IMPEL NEUROPHARMA INC (Filer) CIK: 0001445499 (see all company filings)

IRS No.: 263058238 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40353 | Film No.: 22746838
SIC: 2834 Pharmaceutical Preparations